Floatz Rating
B60/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01267266CT.gov Saracatinib in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT01036594CT.gov Ketoconazole and Dexamethasone in Prostate Cancer | — | Completed | — | — | — |
NCT00953576CT.gov Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer | — | Terminated | — | — | — |
NCT00859781CT.gov 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT00895310CT.gov Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy | — | Completed | — | — | — |
NCT00559481CT.gov Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy | — | Withdrawn | — | — | — |
NCT00536991CT.gov Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT00460031CT.gov Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | — | Completed | — | — | — |
NCT00673127CT.gov Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00309894CT.gov Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy | — | Completed | — | — | — |
Show 7 more trialsShow fewer
NCT00181597CT.gov Trilostane for Androgen-Independent Prostate Cancer | — | Completed | — | — | — |
NCT00027859CT.gov Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00006371CT.gov A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer | — | Terminated | — | — | — |
NCT00002881CT.gov Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00002760CT.gov Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00002855CT.gov Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer | — | Completed | — | — | — |
NCT05974410CT.gov Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hydrocortisone (this asset) | National Cancer Institute (NCI) | P3 | B · 60 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Hydrocortisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Congenital Adrenal Hyperplasia | — | P4 | A · 81 |
| Childhood Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| Adrenocortical Insufficiency | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hydrocortisone in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hydrocortisone-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →